1
|
Lan G, Song Q, Luan Y, Cheng Y. Targeted strategies to deliver boron agents across the blood-brain barrier for neutron capture therapy of brain tumors. Int J Pharm 2024; 650:123747. [PMID: 38151104 DOI: 10.1016/j.ijpharm.2023.123747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2023] [Revised: 12/21/2023] [Accepted: 12/23/2023] [Indexed: 12/29/2023]
Abstract
Boron neutron capture therapy (BNCT), as an innovative radiotherapy technology, has demonstrated remarkable outcomes when compared to conventional treatments in the management of recurrent and refractory brain tumors. However, in BNCT of brain tumors, the blood-brain barrier is a main stumbling block for restricting the transport of boron drugs to brain tumors, while the tumor targeting and retention of boron drugs also affect the BNCT effect. This review focuses on the recent development of strategies for delivering boron drugs crossing the blood-brain barrier and targeting brain tumors, providing new insights for the development of efficient boron drugs for the treatment of brain tumors.
Collapse
Affiliation(s)
- Gongde Lan
- Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
| | - Qingxu Song
- Department of Radiation Oncology, Boron Neutron Capture Therapy Medical Center, Qilu Hospital of Shandong University, Jinan, Shandong, China
| | - Yuxia Luan
- Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
| | - Yufeng Cheng
- Department of Radiation Oncology, Boron Neutron Capture Therapy Medical Center, Qilu Hospital of Shandong University, Jinan, Shandong, China.
| |
Collapse
|
2
|
Khalil A, Adam MSS. Nucleoside Scaffolds and Carborane Clusters for Boron Neutron Capture Therapy: Developments and Future Perspective. Curr Med Chem 2024; 31:5739-5754. [PMID: 37818562 DOI: 10.2174/0109298673245020230929152030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2023] [Revised: 06/19/2023] [Accepted: 08/24/2023] [Indexed: 10/12/2023]
Abstract
Nucleosides containing carboranes are one of the most important boron delivery agents for boron neutron capture therapy, BNCT, which are good substrates of hTK1. The development of several nucleosides containing carboranes at early stages led to the discovery of the first generation of 3CTAs by incorporating a hydrocarbon spacer between the thymidine scaffold and carborane cluster and attaching dihydroxylpropyl group on the second carbon (C2) atom of the carborane cluster (e.g., N5 and N5-2OH). Phosphorylation rate, tumor cellular uptake, and retention have been evaluated in parallel to change the length of the tether arm of spacers in these compounds. Many attempts were reported and discussed to overcome the disadvantage of the first generation of 3CTAs by a) incorporating modified spacers between thymidine and carborane clusters, such as ethyleneoxide, polyhydroxyl, triazole, and tetrazole units, b) attaching hydrophilic groups at C2 of the carborane cluster, c) transforming lipophilic closo-carboranes to hydrophilic nidocarborane. The previous modifications represented the second generation of 3CTAs to improve the hydrogen bond formation with the hTK1 active site. Moreover, amino acid prodrugs were developed to enhance biological and physicochemical properties. The structure-activity relationship (SAR) of carboranyl thymidine analogues led to the roadmap for the development of the 3rd generation of the 3CTAs for BNCT.
Collapse
Affiliation(s)
- Ahmed Khalil
- Department of Chemistry, College of Science, King Faisal University, Al Ahsa 31982, Saudi Arabia
- Department of Chemistry, Faculty of Science, Zagazig University, Zagazig 44519, Egypt
| | - Mohamed Shaker S Adam
- Department of Chemistry, College of Science, King Faisal University, Al Ahsa 31982, Saudi Arabia
- Department of Chemistry, Faculty of Science, Sohag University, Sohag 82534, Egypt
| |
Collapse
|
3
|
Marforio TD, Carboni A, Calvaresi M. In Vivo Application of Carboranes for Boron Neutron Capture Therapy (BNCT): Structure, Formulation and Analytical Methods for Detection. Cancers (Basel) 2023; 15:4944. [PMID: 37894311 PMCID: PMC10605826 DOI: 10.3390/cancers15204944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 09/22/2023] [Accepted: 10/09/2023] [Indexed: 10/29/2023] Open
Abstract
Carboranes have emerged as one of the most promising boron agents in boron neutron capture therapy (BNCT). In this context, in vivo studies are particularly relevant, since they provide qualitative and quantitative information about the biodistribution of these molecules, which is of the utmost importance to determine the efficacy of BNCT, defining their localization and (bio)accumulation, as well as their pharmacokinetics and pharmacodynamics. First, we gathered a detailed list of the carboranes used for in vivo studies, considering the synthesis of carborane derivatives or the use of delivery system such as liposomes, micelles and nanoparticles. Then, the formulation employed and the cancer model used in each of these studies were identified. Finally, we examined the analytical aspects concerning carborane detection, identifying the main methodologies applied in the literature for ex vivo and in vivo analysis. The present work aims to identify the current strengths and weakness of the use of carboranes in BNCT, establishing the bottlenecks and the best strategies for future applications.
Collapse
Affiliation(s)
| | - Andrea Carboni
- Dipartimento di Chimica “Giacomo Ciamician”, Alma Mater Studiorum—Università di Bologna, Via Francesco Selmi 2, 40126 Bologna, Italy;
| | - Matteo Calvaresi
- Dipartimento di Chimica “Giacomo Ciamician”, Alma Mater Studiorum—Università di Bologna, Via Francesco Selmi 2, 40126 Bologna, Italy;
| |
Collapse
|
4
|
Wang Q, Mu J, Zeng J, Wan L, Zhong Y, Li Q, Li Y, Wang H, Chen F. Additive-controlled asymmetric iodocyclization enables enantioselective access to both α- and β-nucleosides. Nat Commun 2023; 14:138. [PMID: 36627283 PMCID: PMC9831021 DOI: 10.1038/s41467-022-35610-w] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2022] [Accepted: 12/13/2022] [Indexed: 01/11/2023] Open
Abstract
β-Nucleosides and their analogs are dominant clinically-used antiviral and antitumor drugs. α-Nucleosides, the anomers of β-nucleosides, exist in nature and have significant potential as drugs or drug carriers. Currently, the most widely used methods for synthesizing β- and α-nucleosides are via N-glycosylation and pentose aminooxazoline, respectively. However, the stereoselectivities of both methods highly depend on the assisting group at the C2' position. Herein, we report an additive-controlled stereodivergent iodocyclization method for the selective synthesis of α- or β-nucleosides. The stereoselectivity at the anomeric carbon is controlled by the additive (NaI for β-nucleosides; PPh3S for α-nucleosides). A series of β- and α-nucleosides are prepared in high yields (up to 95%) and stereoselectivities (β:α up to 66:1, α:β up to 70:1). Notably, the introduced iodine at the C2' position of the nucleoside is readily functionalized, leading to multiple structurally diverse nucleoside analogs, including stavudine, an FDA-approved anti-HIV agent, and molnupiravir, an FDA-approved anti-SARS-CoV-2 agent.
Collapse
Affiliation(s)
- Qi Wang
- Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China
| | - Jiayi Mu
- Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China
| | - Jie Zeng
- Pharmaceutical Research Institute, Wuhan Institute of Technology, 430205, Wuhan, China
| | - Linxi Wan
- Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China
| | - Yangyang Zhong
- Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China
| | - Qiuhong Li
- Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China
| | - Yitong Li
- Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China
| | - Huijing Wang
- Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China.
| | - Fener Chen
- Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China. .,Engineering Center of Catalysis and synthesis for Chiral Molecules, Department of chemistry, Fudan University, Shanghai, 200433, China. .,Shanghai Engineering Center of Industrial Asymmetric Catalysis for Chiral Drugs, Shanghai, 200433, China.
| |
Collapse
|
5
|
Carboranes in drug discovery, chemical biology and molecular imaging. Nat Rev Chem 2022; 6:486-504. [PMID: 37117309 DOI: 10.1038/s41570-022-00400-x] [Citation(s) in RCA: 40] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/17/2022] [Indexed: 11/08/2022]
Abstract
There exists a paucity of structural innovation and limited molecular diversity associated with molecular frameworks in drug discovery and biomolecular imaging/chemical probe design. The discovery and exploitation of new molecular entities for medical and biological applications will necessarily involve voyaging into previously unexplored regions of chemical space. Boron clusters, notably the carboranes, offer an alternative to conventional (poly)cyclic organic frameworks that may address some of the limitations associated with the use of novel molecular frameworks in chemical biology or medicine. The high thermal stability, unique 3D structure and aromaticity, kinetic inertness to metabolism and ability to engage in unusual types of intermolecular interactions, such as dihydrogen bonds, with biological receptors make carboranes exquisite frameworks in the design of probes for chemical biology, novel drug candidates and biomolecular imaging agents. This Review highlights the key developments of carborane derivatives made over the last decade as new design tools in medicinal chemistry and chemical biology, showcasing the versatility of this unique family of boron compounds.
Collapse
|
6
|
Synthesis, characterization, and in vitro assessment of cytotoxicity for novel azaheterocyclic nido-carboranes – Candidates in agents for boron neutron capture therapy (BNCT) of cancer. Tetrahedron 2021. [DOI: 10.1016/j.tet.2021.132525] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|
7
|
Zharkov DO, Yudkina AV, Riesebeck T, Loshchenova PS, Mostovich EA, Dianov GL. Boron-containing nucleosides as tools for boron-neutron capture therapy. Am J Cancer Res 2021; 11:4668-4682. [PMID: 34765286 PMCID: PMC8569357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Accepted: 07/20/2021] [Indexed: 06/13/2023] Open
Abstract
Despite the significant progress in cancer cure, the development of new approaches to cancer therapy is still of great importance since many deadly tumors remain untreatable. Boron neutron capture therapy (BNCT), proposed more than eighty years ago, is still considered a potentially advantageous approach. Irradiation of cells containing 10B isotopes with epithermal neutrons and the consequent decay of boron nuclei releases particles that deposit high energy along a very short path, inflicting heavy damage on the target cells but sparing the neighbouring tissue. Delivery and preferential accumulation of boron in cancer cells are the major obstacles that slow down the clinical use of BNCT. Since DNA damage caused by irradiation is the major reason for cell death, the incorporation of boron-containing nucleotides into the DNA of cancer cells may significantly increase the efficacy of BNCT. In this review, we discuss the current state of knowledge in the synthesis of boron-containing nucleosides and their application for BNCT with a special focus on their possible incorporation into genomic DNA.
Collapse
Affiliation(s)
- Dmitry O Zharkov
- Novosibirsk State University2 Pirogova Street, Novosibirsk 630090, Russia
- SB RAS Institute of Chemical Biology and Fundamental Medicine8 Lavrentieva Avenue, Novosibirsk 630090, Russia
| | - Anna V Yudkina
- Novosibirsk State University2 Pirogova Street, Novosibirsk 630090, Russia
- SB RAS Institute of Chemical Biology and Fundamental Medicine8 Lavrentieva Avenue, Novosibirsk 630090, Russia
| | - Tim Riesebeck
- Novosibirsk State University2 Pirogova Street, Novosibirsk 630090, Russia
| | - Polina S Loshchenova
- Novosibirsk State University2 Pirogova Street, Novosibirsk 630090, Russia
- SB RAS Institute of Cytology and Genetics10 Lavrentieva Avenue, Novosibirsk 630090, Russia
| | - Evgeny A Mostovich
- Novosibirsk State University2 Pirogova Street, Novosibirsk 630090, Russia
| | - Grigory L Dianov
- Novosibirsk State University2 Pirogova Street, Novosibirsk 630090, Russia
- SB RAS Institute of Cytology and Genetics10 Lavrentieva Avenue, Novosibirsk 630090, Russia
- Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research BuildingOxford OX3 7DQ, United Kingdom
| |
Collapse
|
8
|
Wong AAWL, Lozada J, Lepage ML, Zhang C, Merkens H, Zeisler J, Lin KS, Bénard F, Perrin DM. Synthesis and 18F-radiolabeling of thymidine AMBF 3 conjugates. RSC Med Chem 2020; 11:569-576. [PMID: 33479658 PMCID: PMC7578706 DOI: 10.1039/d0md00054j] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2020] [Accepted: 04/09/2020] [Indexed: 01/08/2023] Open
Abstract
In pursuit of 18F-labeled nucleosides for positron emission tomography (PET) imaging, we report on the chemical and radiochemical synthesis of two thymidine (dT) analogs, dT-C5-AMBF3 and dT-N3-AMBF3, that are radiofluorinated by isotope exchange (IEX) and studied as PET imaging agents in mice with tumor xenografts. dT-C5-AMBF3 shows preferential, and tumor-specific, uptake over dT-N3-AMBF3. This work provides a new synthetic method in order to access new nucleoside tracers for PET imaging.
Collapse
Affiliation(s)
- Antonio A W L Wong
- Department of Chemistry , University of British Columbia (UBC) , 2036 Main Mall , Vancouver , BC , V6T 1Z1 Canada .
| | - Jerome Lozada
- Department of Chemistry , University of British Columbia (UBC) , 2036 Main Mall , Vancouver , BC , V6T 1Z1 Canada .
| | - Mathieu L Lepage
- Department of Chemistry , University of British Columbia (UBC) , 2036 Main Mall , Vancouver , BC , V6T 1Z1 Canada .
| | - Chengcheng Zhang
- Department of Molecular Oncology , B.C. Cancer Research Centre (BCCRC) , 675 West 10th Avenue , Vancouver , BC , V5Z 1L3 Canada
| | - Helen Merkens
- Department of Molecular Oncology , B.C. Cancer Research Centre (BCCRC) , 675 West 10th Avenue , Vancouver , BC , V5Z 1L3 Canada
| | - Jutta Zeisler
- Department of Molecular Oncology , B.C. Cancer Research Centre (BCCRC) , 675 West 10th Avenue , Vancouver , BC , V5Z 1L3 Canada
| | - Kuo-Shyan Lin
- Department of Molecular Oncology , B.C. Cancer Research Centre (BCCRC) , 675 West 10th Avenue , Vancouver , BC , V5Z 1L3 Canada
| | - François Bénard
- Department of Molecular Oncology , B.C. Cancer Research Centre (BCCRC) , 675 West 10th Avenue , Vancouver , BC , V5Z 1L3 Canada
| | - David M Perrin
- Department of Chemistry , University of British Columbia (UBC) , 2036 Main Mall , Vancouver , BC , V6T 1Z1 Canada .
| |
Collapse
|
9
|
|
10
|
Li R, Zhang J, Guo J, Xu Y, Duan K, Zheng J, Wan H, Yuan Z, Chen H. Application of Nitroimidazole-Carbobane-Modified Phenylalanine Derivatives as Dual-Target Boron Carriers in Boron Neutron Capture Therapy. Mol Pharm 2019; 17:202-211. [PMID: 31763850 DOI: 10.1021/acs.molpharmaceut.9b00898] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Boron neutron capture therapy (BNCT) has received extensive attention as noninvasive cell-level oncotherapy for treating solid cancer tumors. However, boron-containing drugs such as l-boronophenylalanine (BPA) and sodium borocaptate have low boron content and/or poor tumor-targeting ability, limiting their application. In this study, we designed and synthesized a series of nontoxic, dual-target boron carriers (B139, B142, and B151) with the ability to accumulate specifically in tumor cells. We found that the B139 uptake into hypoxic tumor regions was high, with a 70-fold boron content compared to BPA. In addition, in vivo observation showed that B139 can be trapped in tumor cells for a prolonged period and maintains an effective therapeutic concentration, with a peak boron concentration of 50.7 μg/g and a high tumor: blood boron ratio of >3, achieving ideal BNCT conditions. Cytotoxicity evaluation in mice further proved that B139 is safe and reliable. Therefore, B139 has great potential for BNCT application as a dual-target, safe, and efficient boron carrier.
Collapse
Affiliation(s)
- Ruixi Li
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| | - Juanjuan Zhang
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| | - Jingxuan Guo
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| | - Yue Xu
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| | - Kunyuan Duan
- Department of Pharmacy , Qujing Medical College , Qujing 655000 , China
| | - Jinrong Zheng
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| | - Hao Wan
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| | - Zhenwei Yuan
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| | - Haiyan Chen
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| |
Collapse
|
11
|
Stockmann P, Gozzi M, Kuhnert R, Sárosi MB, Hey-Hawkins E. New keys for old locks: carborane-containing drugs as platforms for mechanism-based therapies. Chem Soc Rev 2019; 48:3497-3512. [PMID: 31214680 DOI: 10.1039/c9cs00197b] [Citation(s) in RCA: 151] [Impact Index Per Article: 30.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Icosahedral carboranes in medicine are still an emerging class of compounds with potential beneficial applications in drug design. These highly hydrophobic clusters are potential "new keys for old locks" which open up an exciting field of research for well-known, but challenging important therapeutic substrates, as demonstrated by the numerous examples discussed in this review.
Collapse
Affiliation(s)
- Philipp Stockmann
- Universität Leipzig, Fakultät für Chemie und Mineralogie, Institut für Anorganische Chemie, Johannisallee 29, 04103 Leipzig, Germany.
| | | | | | | | | |
Collapse
|
12
|
Comparative study of inorganic, boron-rich cluster and organic, phenyl adenosine modifications: synthesis and properties. Future Med Chem 2019; 11:1267-1284. [DOI: 10.4155/fmc-2018-0517] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Background: Nucleoside analogs are important class of chemotherapeutics. One of the original openings in the nucleoside medicinal chemistry was derivatives comprising a boron cluster component. Results: A series of adenosine derivative pairs containing inorganic boron cluster or alternatively its mimic, organic phenyl modification were synthesized and their physicochemical and biological properties compared. Marked effects of boron clusters, which are qualitatively and quantitatively different from the phenyl group effects, were detected. The studied characteristics include syn/ anti conformation, lipophilicity, cytotoxicity and antiviral activity, as well as phosphorylation by adenosine kinase. Conclusion: The obtained results demonstrate usefulness of the boron clusters for tuning properties of biomolecules and prove their potential as modifying units in design of future therapeutics based on nucleoside structures.
Collapse
|
13
|
Naphthyl quinoxaline thymidine conjugate is a potent anticancer agent post UVA activation and elicits marked inhibition of tumor growth through vaccination. Eur J Med Chem 2019; 171:255-264. [PMID: 30925340 DOI: 10.1016/j.ejmech.2019.03.051] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2019] [Revised: 03/13/2019] [Accepted: 03/19/2019] [Indexed: 12/21/2022]
Abstract
Anticancer anthracyclines are cytotoxic drugs that can induce antitumor immune response as a secondary effect through immunogenic cell death (ICD) mechanism. However, the immunogenic potency is quite limited, possibly due to that these chemotherapeutic agents are not specifically developed as ICD inducers. Thus, new drug entities through studies focusing on enhanced ICD induction would significantly promote antitumor immune response in the vaccination application. We report here a naphthyl quinoxaline thymidine conjugate as a new class of cytotoxic compounds that effectively induced in vivo antitumor activity through the vaccination application. Synthesized naphthyl quinoxaline conjugates were weak fluorescent thymidine analog yet exhibited a pronounced anticancer activity in the low nanomolar range post UVA activation. The potent activity of naphthyl conjugate was able to induce the marked detection of ICD markers including ATP and HMGB1 extracellular and calreticulin intracellularly at 2 h post UVA activation. Most importantly, mice vaccinated with cells treated with naphthyl conjugate plus UVA exhibited complete tumor growth inhibition in the tumor challenge study, and the induced immunogenic inhibition was much more effective than that of mitoxantrone anthracycline drug. All these results demonstrate the high potential of naphthyl quinoxaline conjugate for the cancer cell vaccine against tumor.
Collapse
|
14
|
LA K, LE Z, SF* E, M* T, NS* H. Synthesis and Biological Evaluation of Fluorescein-Tagged 1-Methyl-o-carborane for Boron Neutron Capture Therapy. ACTA ACUST UNITED AC 2018. [DOI: 10.29328/journal.aac.1001016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
15
|
Yinghuai Z, Lin X, Xie H, Li J, Hosmane NS, Zhang Y. The Current Status and Perspectives of Delivery Strategy for Boron-based Drugs. Curr Med Chem 2018; 26:5019-5035. [PMID: 30182851 DOI: 10.2174/0929867325666180904105212] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2018] [Revised: 07/26/2018] [Accepted: 07/27/2018] [Indexed: 12/27/2022]
Abstract
Boron-containing compounds are essential micronutrients for animals and plants despite their low-level natural occurrence. They can strengthen the cell walls of the plants and they play important role in supporting bone health. However, surprisingly, boron-containing compounds are seldom found in pharmaceutical drugs. In fact, there are no inherent disadvantages reported so far in terms of the incorporation of boron into medicines. Indeed, drugs based on boron-containing compounds, such as tavaborole (marked name Kerydin) and bortezomib (trade name Velcade) have been investigated and they are used in clinical treatment. In addition, following the advanced development of boron neutron capture therapy and a new emerging proton boron fusion therapy, more boron-containing medicinals are to be expected. This review discusses the current status and perspectives of delivery strategy for boron-containing drugs.
Collapse
Affiliation(s)
- Zhu Yinghuai
- School of Pharmacy, Macau University of Science and Technology, Avenida Wai Long, Taipa 999078, Macau. Macao
| | - Xinglong Lin
- New Drug Research Institute, HEC Pharma Group, Dongguan 523871. China
| | - Hongming Xie
- New Drug Research Institute, HEC Pharma Group, Dongguan 523871. China
| | - Jianlin Li
- HEC Research and Development Center, Dongguan 523871. China
| | - Narayan S Hosmane
- Department of Chemistry and Biochemistry, Northern Illinois University, DeKalb, Illinois 60115-2862. United States
| | - Yingjun Zhang
- New Drug Research Institute, HEC Pharma Group, Dongguan 523871. China
| |
Collapse
|
16
|
Synthesis, susceptibility to enzymatic phosphorylation, cytotoxicity and in vitro antiviral activity of lipophilic pyrimidine nucleoside/carborane conjugates. J Organomet Chem 2018. [DOI: 10.1016/j.jorganchem.2018.03.026] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
17
|
Rahman MF, Raj R, Govindarajan R. Identification of Structural and Molecular Features Involved in the Transport of 3'-Deoxy-Nucleoside Analogs by Human Equilibrative Nucleoside Transporter 3. Drug Metab Dispos 2018. [PMID: 29530865 PMCID: PMC5896370 DOI: 10.1124/dmd.117.079400] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Combination antiretroviral drug treatments depend on 3′-deoxy-nucleoside analogs such as 3′-azido-3′-deoxythymidine (AZT) and 2′3′-dideoxyinosine (DDI). Despite being effective in inhibiting human immunodeficiency virus replication, these drugs produce a range of toxicities, including myopathy, pancreatitis, neuropathy, and lactic acidosis, that are generally considered as sequelae to mitochondrial damage. Although cell surface–localized nucleoside transporters, such as human equilibrative nucleoside transporter 2 (hENT2) and human concentrative nucleoside transporter 1 (hCNT1), are known to increase the carrier-mediated uptake of 3′-deoxy-nucleoside analogs into cells, another ubiquitously expressed intracellular nucleoside transporter (namely, hENT3) has been implicated in the mitochondrial transport of 3′-deoxy-nucleoside analogs. Using site-directed mutagenesis, generation of chimeric hENTs, and 3H-permeant flux measurements in mutant/chimeric RNA–injected Xenopus oocytes, here we identified the molecular determinants of hENT3 that dictate membrane translocation of 3′-deoxy-nucleoside analogs. Our findings demonstrated that whereas hENT1 had no significant transport activity toward 3′-deoxy-nucleoside analogs, hENT3 was capable of transporting 3′-deoxy-nucleoside analogs similar to hENT2. Transport analyses of hENT3-hENT1 chimeric constructs demonstrated that the N-terminal half of hENT3 is primarily responsible for the hENT3–3′-deoxy-nucleoside analog interaction. In addition, mutagenic studies identified that 225D and 231L in the N-terminal half of hENT3 partially contribute to the ability of hENT3 to transport AZT and DDI. The identification of the transporter segment and amino acid residues that are important in hENT3 transport of 3′-deoxy-nucleoside analogs may present a possible mechanism for overcoming the adverse toxicities associated with 3′-deoxy-nucleoside analog treatment and may guide rational development of novel nucleoside analogs.
Collapse
Affiliation(s)
- Md Fazlur Rahman
- Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy (M.F.R., R.R., R.G.) and Translational Therapeutics, Ohio State University Comprehensive Cancer Center (R.G.), The Ohio State University, Columbus, Ohio
| | - Radhika Raj
- Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy (M.F.R., R.R., R.G.) and Translational Therapeutics, Ohio State University Comprehensive Cancer Center (R.G.), The Ohio State University, Columbus, Ohio
| | - Rajgopal Govindarajan
- Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy (M.F.R., R.R., R.G.) and Translational Therapeutics, Ohio State University Comprehensive Cancer Center (R.G.), The Ohio State University, Columbus, Ohio
| |
Collapse
|
18
|
Dąbrowska A, Matuszewski M, Zwoliński K, Ignaczak A, Olejniczak AB. Insight into lipophilicity of deoxyribonucleoside‑boron cluster conjugates. Eur J Pharm Sci 2018; 111:226-237. [DOI: 10.1016/j.ejps.2017.09.036] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2017] [Revised: 09/21/2017] [Accepted: 09/24/2017] [Indexed: 01/14/2023]
|
19
|
Carborane-containing urea-based inhibitors of glutamate carboxypeptidase II: Synthesis and structural characterization. Bioorg Med Chem Lett 2015; 25:5232-6. [DOI: 10.1016/j.bmcl.2015.09.062] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2015] [Revised: 08/29/2015] [Accepted: 09/24/2015] [Indexed: 01/13/2023]
|
20
|
Evaluation of TK1 targeting carboranyl thymidine analogs as potential delivery agents for neutron capture therapy of brain tumors. Appl Radiat Isot 2015; 106:251-5. [PMID: 26282567 DOI: 10.1016/j.apradiso.2015.06.031] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2014] [Revised: 05/11/2015] [Accepted: 06/25/2015] [Indexed: 01/26/2023]
Abstract
In this report we describe studies with N5-2OH, a carboranyl thymidine analog (CTA), which is a substrate for thymidine kinase 1 (TK1), using the F98 rat glioma model. In vivo BNCT studies have demonstrated that intracerebral (i.c.) osmotic pump infusion of N5-2OH yielded survival data equivalent to those obtained with i.v. administration of boronophenylalanine (BPA). The combination of N5-2OH and BPA resulted in a modest increase in MST of F98 glioma bearing rats compared to a statistically significant increase with the RG2 glioma model, as has been previously reported by us (Barth et al., 2008). This had lead us to synthesize a second generation of CTAs that have improved in vitro enzyme kinetics and in vivo tumor uptake (Agarwal et al., 2015).
Collapse
|